Premium
Puerarin inhibits the development of osteoarthritis through antiinflammatory and antimatrix‐degrading pathways in osteoarthritis‐induced rat model
Author(s) -
Ma Tianwen,
Wen Yajing,
Song Xiaopeng,
Hu Hailong,
Li Yue,
Bai Hui,
Zhao Mingchao,
Gao Li
Publication year - 2021
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6988
Subject(s) - puerarin , celecoxib , osteoarthritis , pueraria , medicine , pharmacology , cartilage , endocrinology , pathology , anatomy , alternative medicine
Puerarin is an isoflavone isolated from the medicinal plant Pueraria lobata . The purpose of this study was to study the antiinflammatory and antimatrix‐degrading effects of puerarin in a rat osteoarthritis (OA) model and its protective effects on joints. The rat OA model was established by anterior cruciate ligament transection (ACLT) surgery. Rats ( n = 40) were divided into nontreated OA, OA + celecoxib (2.86 mg/kg), OA + puerarin (50 and 100 mg/kg), and control groups. Two weeks after surgical induction, puerarin was administered by gavage daily for 8 weeks. After 8 weeks, macroscopic observation and histopathological images showed that cartilage damage was reduced after puerarin and celecoxib treatment, the intensity of Safranin O staining was high, and the OARSI scores were significantly reduced compared to the OA group. Puerarin reduced the expression of MMP‐3, MMP‐13, ADAMTS‐5, and COX‐2 in the cartilage tissue of ACLT rats, inhibited the production of IL‐1β, IL‐6, and TNF‐α inflammatory factors, increased Type II collagen content, and altered the expression of serum OA cartilage degradation/bone turnover biomarkers (CTX‐I, CTX‐II, COMP, and PIINP). Based on these findings, we speculate that puerarin supplement to attain recovery from OA damage.